OMIC logo

OMIC Stock Overview

Profile

Full Name:

Singular Genomics Systems, Inc.

Sector:

Healthcare

Country:

United States

IPO:

May 27, 2021

Indexes:

Not included

Description:

OMIC, part of Singular Genomics Systems, focuses on advanced genomic sequencing technology. They develop innovative tools for researchers and healthcare providers, enabling faster and more accurate analysis of genetic information. Their goal is to improve personalized medicine and enhance our understanding of diseases through better genomic insights.

Key Details

Price

$19.93

Annual Revenue

$2.91 M(+280.52% YoY)

Annual EPS

-$39.00(-1.56% YoY)

Annual ROE

-43.17%

Beta

0.79

Events Calendar

Earnings

Next earnings date:

Mar 18, 2025

Recent quarterly earnings:

Nov 12, 2024

Recent annual earnings:

Mar 18, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Jun 26, 2024

Analyst ratings

Recent major analysts updates

Jul 9, 24 Goldman Sachs
Neutral
May 15, 24 Goldman Sachs
Neutral
Mar 20, 24 UBS
Neutral
Jan 23, 24 Goldman Sachs
Neutral
Jan 22, 24 Goldman Sachs
Neutral
Aug 10, 23 Goldman Sachs
Neutral
Nov 8, 22 Goldman Sachs
Neutral
Aug 17, 22 UBS
Neutral
Aug 10, 22 Goldman Sachs
Neutral
Aug 10, 22 B of A Securities
Underperform

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

Singular Genomics Systems, Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Shareholders With Losses To Reach Out
Singular Genomics Systems, Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Shareholders With Losses To Reach Out
Singular Genomics Systems, Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Shareholders With Losses To Reach Out
OMIC
accessnewswire.comJanuary 29, 2025

LOS ANGELES, CA / ACCESS Newswire / January 29, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Singular Genomics Systems, Inc. ("Singular Genomics" or "the Company") (NASDAQ:OMIC) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Singular Genomics board breached its fiduciary duties to shareholders.

OMIC Investors Have the Opportunity to Join Investigation of Singular Genomics Systems, Inc. with the Schall Law Firm
OMIC Investors Have the Opportunity to Join Investigation of Singular Genomics Systems, Inc. with the Schall Law Firm
OMIC Investors Have the Opportunity to Join Investigation of Singular Genomics Systems, Inc. with the Schall Law Firm
OMIC
prnewswire.comJanuary 28, 2025

LOS ANGELES , Jan. 28, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Singular Genomics Systems, Inc. ("Singular Genomics" or "the Company") (NASDAQ: OMIC) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Singular Genomics board breached its fiduciary duties to shareholders.

Singular Genomics Systems, Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Affected Shareholders To Reach Out
Singular Genomics Systems, Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Affected Shareholders To Reach Out
Singular Genomics Systems, Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Affected Shareholders To Reach Out
OMIC
accessnewswire.comJanuary 27, 2025

LOS ANGELES, CA / ACCESS Newswire / January 27, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Singular Genomics Systems, Inc. ("Singular Genomics" or "the Company") (NASDAQ:OMIC) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Singular Genomics board breached its fiduciary duties to shareholders.

Investors Are Invited To Join The Schall Law Firm In An Inquiry Into Singular Genomics Systems, Inc. For Securities Fraud
Investors Are Invited To Join The Schall Law Firm In An Inquiry Into Singular Genomics Systems, Inc. For Securities Fraud
Investors Are Invited To Join The Schall Law Firm In An Inquiry Into Singular Genomics Systems, Inc. For Securities Fraud
OMIC
accessnewswire.comJanuary 26, 2025

LOS ANGELES, CA / ACCESS Newswire / January 26, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Singular Genomics Systems, Inc. ("Singular Genomics" or "the Company") (NASDAQ:OMIC) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Singular Genomics board breached its fiduciary duties to shareholders.

Singular Genomics Systems, Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Affected Shareholders To Reach Out
Singular Genomics Systems, Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Affected Shareholders To Reach Out
Singular Genomics Systems, Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Affected Shareholders To Reach Out
OMIC
accessnewswire.comJanuary 25, 2025

LOS ANGELES, CA / ACCESS Newswire / January 25, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Singular Genomics Systems, Inc. ("Singular Genomics" or "the Company") (NASDAQ:OMIC) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Singular Genomics board breached its fiduciary duties to shareholders.

Investors With Losses Are Invited To Join The Schall Law Firm In An Inquiry Into Singular Genomics Systems, Inc. For Securities Fraud
Investors With Losses Are Invited To Join The Schall Law Firm In An Inquiry Into Singular Genomics Systems, Inc. For Securities Fraud
Investors With Losses Are Invited To Join The Schall Law Firm In An Inquiry Into Singular Genomics Systems, Inc. For Securities Fraud
OMIC
accessnewswire.comJanuary 24, 2025

LOS ANGELES, CA / ACCESS Newswire / January 24, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Singular Genomics Systems, Inc. ("Singular Genomics" or "the Company") (NASDAQ:OMIC) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Singular Genomics board breached its fiduciary duties to shareholders.

Singular Genomics Systems, Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Affected Shareholders To Reach Out
Singular Genomics Systems, Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Affected Shareholders To Reach Out
Singular Genomics Systems, Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Affected Shareholders To Reach Out
OMIC
accessnewswire.comJanuary 23, 2025

LOS ANGELES, CA / ACCESS Newswire / January 23, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Singular Genomics Systems, Inc. ("Singular Genomics" or "the Company") (NASDAQ:OMIC) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Singular Genomics board breached its fiduciary duties to shareholders.

Singular Genomics Systems, Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Affected Shareholders To Reach Out
Singular Genomics Systems, Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Affected Shareholders To Reach Out
Singular Genomics Systems, Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Affected Shareholders To Reach Out
OMIC
accessnewswire.comJanuary 21, 2025

LOS ANGELES, CA / ACCESS Newswire / January 21, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Singular Genomics Systems, Inc. ("Singular Genomics" or "the Company") (NASDAQ:OMIC) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Singular Genomics board breached its fiduciary duties to shareholders.

Investors With Losses Are Invited To Join The Schall Law Firm In An Inquiry Into Singular Genomics Systems, Inc. For Securities Fraud
Investors With Losses Are Invited To Join The Schall Law Firm In An Inquiry Into Singular Genomics Systems, Inc. For Securities Fraud
Investors With Losses Are Invited To Join The Schall Law Firm In An Inquiry Into Singular Genomics Systems, Inc. For Securities Fraud
OMIC
accessnewswire.comJanuary 20, 2025

LOS ANGELES, CA / ACCESS Newswire / January 20, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Singular Genomics Systems, Inc. ("Singular Genomics" or "the Company") (NASDAQ:OMIC) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Singular Genomics board breached its fiduciary duties to shareholders.

Singular Genomics Systems, Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Affected Shareholders To Reach Out
Singular Genomics Systems, Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Affected Shareholders To Reach Out
Singular Genomics Systems, Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Affected Shareholders To Reach Out
OMIC
accessnewswire.comJanuary 19, 2025

LOS ANGELES, CA / ACCESS Newswire / January 19, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Singular Genomics Systems, Inc. ("Singular Genomics" or "the Company") (NASDAQ:OMIC) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Singular Genomics board breached its fiduciary duties to shareholders.

  • 1(current)
  • 2
  • 3
  • 1(current)
  • 2
  • 3

FAQ

  • What is the ticker symbol for Singular Genomics Systems?
  • Does Singular Genomics Systems pay dividends?
  • What sector is Singular Genomics Systems in?
  • What industry is Singular Genomics Systems in?
  • What country is Singular Genomics Systems based in?
  • When did Singular Genomics Systems go public?
  • Is Singular Genomics Systems in the S&P 500?
  • Is Singular Genomics Systems in the NASDAQ 100?
  • Is Singular Genomics Systems in the Dow Jones?
  • When was Singular Genomics Systems's last earnings report?
  • When does Singular Genomics Systems report earnings?
  • Should I buy Singular Genomics Systems stock now?

What is the ticker symbol for Singular Genomics Systems?

The ticker symbol for Singular Genomics Systems is NASDAQ:OMIC

Does Singular Genomics Systems pay dividends?

No, Singular Genomics Systems does not pay dividends

What sector is Singular Genomics Systems in?

Singular Genomics Systems is in the Healthcare sector

What industry is Singular Genomics Systems in?

Singular Genomics Systems is in the Medical Instruments & Supplies industry

What country is Singular Genomics Systems based in?

Singular Genomics Systems is headquartered in United States

When did Singular Genomics Systems go public?

Singular Genomics Systems's initial public offering (IPO) was on May 27, 2021

Is Singular Genomics Systems in the S&P 500?

No, Singular Genomics Systems is not included in the S&P 500 index

Is Singular Genomics Systems in the NASDAQ 100?

No, Singular Genomics Systems is not included in the NASDAQ 100 index

Is Singular Genomics Systems in the Dow Jones?

No, Singular Genomics Systems is not included in the Dow Jones index

When was Singular Genomics Systems's last earnings report?

Singular Genomics Systems's most recent earnings report was on Nov 12, 2024

When does Singular Genomics Systems report earnings?

The next expected earnings date for Singular Genomics Systems is Mar 18, 2025

Should I buy Singular Genomics Systems stock now?

As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions